Effect of ketoprofen and tolfenamic acid on intravenous pharmacokinetics of ceftriaxone in sheep

ArticleAçık Erişim

Özet

In this study, the pharmacokinetics of ceftriaxone (40 mg/kg) was determined following a single intravenous (IV) administration of ceftriaxone alone and co-administration with ketoprofen (3 mg/kg) or tolfenamic acid (2 mg/kg) in sheep. Eight healthy Akkaraman sheep (2.4 ± 0.3 years and 44 ± 4 kg of body weight) were used. The study was carried out according to the longitudinal design in three periods with a 15-day washout period between administrations. In the first period, sheep received ceftriaxone alone via an IV injection. In the second and third periods, the same sheep received ceftriaxone in combination with ketoprofen and tolfenamic acid, respectively. Plasma concentrations of ceftriaxone were assayed by high-performance liquid chromatography and analyzed using non-compartmental analysis. Following the administration of ceftriaxone alone, the elimination half-life (t1/2ʎz), area under the plasma concentration–time curve from zero (0) hours to infinity (∞) (AUC0-∞), total clearance (ClT), and volume of distribution at steady state were 1.42 h, 182.41 h*µg/ml, 0.22 L/h/kg, and 0.17 L/kg, respectively. While ketoprofen and tolfenamic acid significantly increased the t1/2ʎz and AUC0-∞ of ceftriaxone, they significantly reduced the ClT. Ceftriaxone (40 mg/kg, IV) in concurrent use with ketoprofen and tolfenamic acid can be administrated at the 12 h dosing intervals to maintain T> minimum inhibitory concentration (MIC) values above 60% in the treatment of infections caused by susceptible pathogens with the MIC value of ≤0.75 and ≤1 μg/mL, respectively, in sheep with an inflammatory condition. © 2021 John Wiley & Sons Ltd.

Anahtar Kelimeler

RDL Kalıcı Bağlantı (PID)
https://rdlopen.rawdatalibrary.net/r/ebyu/13386Resmi atıflarda kullanılan kalıcı adres
DOI
https://doi.org/10.1111/jvp.13001Yayıncı resmi DOI adresi
Tam Kayıt
AlanDeğerDil
dc.contributor.authorCetin, Gul
dc.contributor.authorDurna Corum, Duygu
dc.contributor.authorCorum, Orhan
dc.contributor.authorAtik, Orkun
dc.contributor.authorCoskun, Devran
dc.contributor.authorUney, Kamil
dc.date.accessioned2026-10-18T20:28:13.573623169Z
dc.date.available2026-10-18T20:28:13.573623169Z
dc.date.issued2021
dc.description.abstractIn this study, the pharmacokinetics of ceftriaxone (40 mg/kg) was determined following a single intravenous (IV) administration of ceftriaxone alone and co-administration with ketoprofen (3 mg/kg) or tolfenamic acid (2 mg/kg) in sheep. Eight healthy Akkaraman sheep (2.4 ± 0.3 years and 44 ± 4 kg of body weight) were used. The study was carried out according to the longitudinal design in three periods with a 15-day washout period between administrations. In the first period, sheep received ceftriaxone alone via an IV injection. In the second and third periods, the same sheep received ceftriaxone in combination with ketoprofen and tolfenamic acid, respectively. Plasma concentrations of ceftriaxone were assayed by high-performance liquid chromatography and analyzed using non-compartmental analysis. Following the administration of ceftriaxone alone, the elimination half-life (t1/2ʎz), area under the plasma concentration–time curve from zero (0) hours to infinity (∞) (AUC0-∞), total clearance (ClT), and volume of distribution at steady state were 1.42 h, 182.41 h*µg/ml, 0.22 L/h/kg, and 0.17 L/kg, respectively. While ketoprofen and tolfenamic acid significantly increased the t1/2ʎz and AUC0-∞ of ceftriaxone, they significantly reduced the ClT. Ceftriaxone (40 mg/kg, IV) in concurrent use with ketoprofen and tolfenamic acid can be administrated at the 12 h dosing intervals to maintain T> minimum inhibitory concentration (MIC) values above 60% in the treatment of infections caused by susceptible pathogens with the MIC value of ≤0.75 and ≤1 μg/mL, respectively, in sheep with an inflammatory condition. © 2021 John Wiley & Sons Ltd.
dc.description.sponsorshipFunding text 1: This study was supported by The Coordination of Scientific Research Projects, University of Erzincan Binali Yıldırım, Turkey (Project No. TSA‐2019‐522). The abstract form of study was presented as oral presentation to 2th International Health Sciences and Innovation Congress, Ankara, Turkey, September 27‐28, 2020. ; Funding text 2: This study was supported by The Coordination of Scientific Research Projects, University of Erzincan Binali Y?ld?r?m, Turkey (Project No. TSA-2019-522). The abstract form of study was presented as oral presentation to 2th International Health Sciences and Innovation Congress, Ankara, Turkey, September 27-28, 2020.
dc.identifier.doi10.1111/jvp.13001
dc.identifier.eissn1365-2885
dc.identifier.endpage951
dc.identifier.issn0140-7783
dc.identifier.issue6
dc.identifier.pmid34312894
dc.identifier.scopus2-s2.0-85111259601
dc.identifier.startpage945
dc.identifier.urihttps://rdlopen.rawdatalibrary.net/r/ebyu/13386
dc.identifier.volume44
dc.identifier.wosWOS:000678980300001
dc.language.isoen
dc.publisherJohn Wiley and Sons Inc
dc.relation.ispartofJournal of Veterinary Pharmacology and Therapeutics
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectceftriaxone
dc.subjectketoprofen
dc.subjectpharmacokinetics
dc.subjectsheep
dc.subjecttolfenamic acid
dc.subjectAnimals
dc.subjectArea Under Curve
dc.subjectHalf-Life
dc.subjectInjections, Intravenous
dc.subjectortho-Aminobenzoates
dc.subjecttolfine
dc.subjectvilprofen
dc.subjectanthranilic acid derivative
dc.subjectAkkaraman sheep
dc.subjectanimal experiment
dc.subjectarea under the curve
dc.subjectArticle
dc.subjectconcentration response
dc.subjectcontrolled study
dc.subjectdrug blood level
dc.subjectdrug clearance
dc.subjectdrug effect
dc.subjectelimination half-life
dc.subjectfemale
dc.subjecthigh performance liquid chromatography
dc.subjectlongitudinal study
dc.subjectminimum inhibitory concentration
dc.subjectnonhuman
dc.subjectplasma concentration-time curve
dc.subjectsingle drug dose
dc.titleEffect of ketoprofen and tolfenamic acid on intravenous pharmacokinetics of ceftriaxone in sheep
dc.typeArticle
dspace.entity.typePublication
rdl.citation.scopus7
rdl.citation.wos7
rdl.departmentDepartment of Pharmacology, Faculty of Pharmacy, University of Erzincan Binali Yıldırım, Erzincan, Turkey.
rdl.source.indexSCOPUS
rdl.source.indexWOS
rdl.source.indexPUBMED
rdl.wos.indexScience Citation Index Expanded (SCI-EXPANDED)